The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/183973

Please be advised that this information was generated on 2020-02-14 and may be subject to change.
OLT1177, a β-sulfonyl nitrite compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation


Activation of the NLRP3 inflammasome induces maturation of IL-1β and IL-18, both validated targets for treating acute and chronic inflammatory diseases. Here, we demonstrate that OLT1177, an orally active β-sulfonyl nitrite molecule, inhibits activation of the NLRP3 inflammasome. In vitro, nanomolar concentrations of OLT1177 reduced IL-1β and IL-1β release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLR4 and AIM2 inflammasomes, suggesting specificity for NLRP3. In LPS-stimulated human blood-derived macrophages, OLT1177 decreased IL-1β levels by 60% and IL-1β by 70% at concentrations 100-fold lower in vitro than plasma concentrations safely reached in humans. OLT1177 also reduced IL-1β and caspase-1 activity in freshly obtained human blood neutrophils. In monocytes isolated from patients with cryopyrin-associated periodic syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1β release by 84% and 36%. Immunoprecipitation and FRET analysis demonstrated that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 interaction, thus inhibiting NLRP3 inflammasome oligomerization. In a cell-free assay, OLT1177 reduced ATPase activity of recombinant NLRP3, suggesting direct targeting of NLRP3. Mechanistically, OLT1177 did not affect potassium efflux, gene expression, or synthesis of the IL-1β precursor. Steady-state levels of phosphorylated NF-κB and IκB kinase were significantly lowered in spleen cells from OLT1177-treated mice. We observed reduced IL-1β content in tissue homogenates, limited oxidative stress, and increased muscle oxidative metabolism. In LPS-treated mice, OLT1177 reversed the metabolic cost of inflammation and improved muscle function. Healthy humans receiving 1,000 mg of OLT1177 daily for 8 d exhibited neither adverse effects nor biochemical or hematological changes.

Interleukin-1β (IL-1β) is the prototypic inflammatory cytokine that promotes acute and chronic inflammation in a broad spectrum of diseases (1). Lacking a leader sequence, the IL-1β precursor requires maturation into an active cytokine by caspase-1. Activation of caspase-1 takes place by the oligomerization of intracellular proteins, termed inflammasomes, which induce the autocatalytic activation of caspase-1 (2, 3). Whereas several inflammasomes have been described, the NOD-like receptor (NLR) protein 3 (NLRP3) (also known as cryopyrin) has been extensively characterized for its role in models of disease (4, 5). Processing and secretion of active IL-1β and IL-18 via caspase-1 follows activation of the NLRP3 inflammasome. Pharmacologic inhibition or genetic deficiency of NLRP3 results in markedly reduced inflammation in animal models of human disease (6–8). Microbial products via Toll-like receptors (TLRs), host products generated during damaging inflammation, as well as IL-1 itself, activate NLRP3, which leads to release of active IL-1β and IL-18. Although neutralization of IL-1 has proven efficacious in the treatment of inflammation, to date, there is no approved therapeutic that inhibits the activation of the NLRP3 inflammasome in humans. OLT1177 is an active moiety discovered during the investigation of synthetic reactions containing chlorinating agents and methionine. Structural elucidation established that OLT1177 is a β-sulfonyl nitrite (formula weight 133.17). We report here that OLT1177 is a selective inhibitor of the NLRP3 inflammasome. We also report that, in healthy humans, OLT1177 is safe at oral doses up to 1,000 mg each day for 8 d, with no clinical, hematological, or organ toxicities observed. Thus, OLT1177 has the potential for the treatment of IL-1β- and IL-18-mediated diseases.

Significance

The NLRP3 inflammasome is an intracellular oligomer regulating the activation of caspase-1 for the processing and secretion of IL-1β and IL-18. Although there is growing evidence to substantiate inflammasome inhibition as a therapeutic option for the treatment of inflammatory diseases, to date, there are no approved humans agents. OLT1177, a β-sulfonyl nitrite molecule, shown to be safe in humans, is a selective inhibitor of the NLRP3 inflammasome, with unique properties to reverse the metabolic costs of inflammation and to treat IL-1β- and IL-18-mediated diseases.


Conflict of interest statement: C.A.D. serves as Chairman of Olatec’s Scientific Advisory Board, is co-Chief Scientific Officer, and receives compensation. L.A.B.J. serves on Olatec’s Scientific Advisory Board and receives compensation. J.P.S.L. has equity in Olatec. D.B.S. serves as Chairman and Chief Executive Officer of Olatec; R.B.B. serves as Chief Operating Officer of Olatec, and C.L.S. and R.D.A. serve on Olatec’s Scientific Advisory Board.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

1To whom correspondence should be addressed. Email: cdinare333@aol.com.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716095115/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1716095115

Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved December 29, 2017 (received for review September 14, 2017)
Results
OLT1177 Suppresses IL-1β and IL-18 Release with No Effect on Priming or TNFα. The structure of OLT1177 is depicted in Fig. 1A and is verified as described in SI Appendix, Figs. S1–S4. We evaluated the effect of OLT1177 on cytokine production in murine and human macrophages following NLRP3 inflammasome activation. In the murine macrophages cell line J774A.1, nanomolar concentrations of OLT1177 reduced IL-1β secretion by 50% following LPS/ATP stimulation (Fig. 1B). In human monocyte-derived macrophages (HMDMs), OLT1177 showed maximal inhibition (60%) of IL-1β and (70%) of IL-18 secretion at 1 μM (SI Appendix, Fig. S5 A and B). By Western blotting, mature IL-1β and the generation of the p10 subunit of active caspase-1 were reduced in the supernatant at 1 and 10 μM OLT1177 (Fig. 1C). In cell lysates, activated caspase-1 was reduced by 35% (P = 0.003) (SI Appendix, Fig. S5C) whereas there were no changes in the intracellular level of the IL-1β and caspase-1 precursors (Fig. 1 C and D). In the same supernatants, OLT1177 showed no effect in TNFα levels (Fig. 1E). Similar to cultures stimulated with LPS/ATP, OLT1177 inhibited IL-1β release in murine macrophages stimulated with LPS and nigericin (Fig. 1F), without affecting TNFα levels (Fig. 1G). Although LPS/ATP stimulation can result in lactate dehydrogenase (LDH) release as a measure of cell death, in the presence of OLT1177, the release of LDH was significantly reduced (P < 0.05) (Fig. 1H). To further investigate potential effects of OLT1177 on gene expression, mRNA levels of nlrp3, asc, caspase1, il1b, and il18 were measured. As shown in SI Appendix, Fig. S5 D–H, OLT1177 had no effect on mRNA levels of these genes, suggesting no effect on the priming phase of the NLRP3 inflammasome formation.

Fig. 1. OLT1177 reduces IL-1β but not TNFα following NLRP3 inflammasome activation. (A) OLT1177 structure. (B) Mean ± SEM percent change (range 270 to 860 pg/mL) of secreted mature IL-1β from J774A.1 cells stimulated with LPS and ATP in the presence of increasing concentration of OLT1177. (C) Western blots for IL-1β (p17 and IL-1β precursor) and caspase-1 (p10 and p45) of supernatant (Sup) and cell lysates (Lys) from J774A.1 cells stimulated with LPS and ATP in the presence of OLT1177. (D) Mean ± SEM percent change (range 375 to 720 pg/mL) of total IL-1β protein level from J774A.1 cell lysates stimulated with LPS and ATP in the presence of OLT1177. (E) Mean ± SEM percent change (range 4,060 to 18,800 pg/mL) of secreted mature TNFα from J774A.1 cells stimulated with LPS and ATP in the presence of increasing concentration of OLT1177. (F and G) Mean ± SEM percent change of secreted mature IL-1β (range 100 to 3,024 pg/mL) (F) and TNFα (range 10,900 to 14,300 pg/mL) (G) from J774A.1 cells stimulated with LPS and nigericin (NIG) in the presence of OLT1177. (H) Mean ± SEM of LDH from J774A.1 cells stimulated with LPS and ATP in the presence of increasing concentration of OLT1177. Percent changes are calculated as described in Methods. The black bars represent the percent of IL-1β, TNFα, and LDH that is still expressed after treatment. ***P < 0.001, *P < 0.05. Data are representative of three independent experiments.

Marchetti et al.

PNAS | Published online January 29, 2018 | E1531
Noncanonical activation of the NLRP3 inflammasome by intracellular LPS leads to an alternative inflammasome pathway, mediated by caspase-4 in humans and caspase-11 in mice (9). We examined IL-1β release in human THP-1 cells stimulated with the TLR2/4 agonist Pam3CSK4, followed by transfection with LPS in WT and nlrp3-deficient cells. As shown in SI Appendix, Fig. S6, treatment with OLT1177 reduced IL-1β release in THP-1 cells, with maximal inhibition (70%) at 10 μM (P < 0.001). Cells deficient in nlp3 showed low or no production of IL-1β, confirming the requirement of NLRP3 for IL-1β release in this model (SI Appendix, Fig. S6).

**Fig. 2.** OLT1177 inhibits NLRP3 inflammasome formation. (A) Immunoprecipitation (IP, Left) and analysis (Right, mean of 3 ± SEM) of the NLRP3-ASC association in J774A.1 cells stimulated with LPS/nigericin (NIG). (B) ATPase activity of recombinant NLRP3 in the presence of OLT1177 (n = 3), Bay11-7082 (BAY) (n = 2), and 3,4-methylenedioxy-β-nitrostyrene (MNS) (n = 2). (C–E) Immunofluorescent staining and (F–H) FRET from NLRP3 (in red) and ASC (in green) in J774A.1 cells stimulated with LPS and NIG in presence of OLT1177 (10 μM). Representative ASC speck-like structures are indicated (white arrows) and highlighted in the Inset (D). Images were acquired using Slide Book 6 (Intelligent Imaging Innovation). (I and J) Mean ± SEM of FRET intensity from NLRP3-ASC (I) and percent change of FRET intensity from NLRP3-caspase-1 (J). ***P < 0.001, **P < 0.01, *P < 0.05. The data are mean of three independent experiments. a.l.u.f.i., arbitrary linear units of fluorescence intensity.
We next examined the effect of OLT1177 on downstream kinase phosphorylation activity in HMDM stimulated with LPS and nigericin. As depicted in SI Appendix, Fig. S7A, OLT1177 reduced several phosphorylated kinases. For example, there was a 26% reduction in Src activation, which, among other functions, activates the NF-κB pathway (10, 11); a 35% reduction in Fyn, which is involved in T-cell activation and motility (12, 13); a 43% reduction in the neutrophil activating kinase Hck (14); and a 33% reduction in STAT3, which affects autoimmune diseases and cancer (15). To demonstrate that OLT1177 does not influence LPS-mediated NF-κB activation, we used the specific IκB kinase inhibitor (IKKi) (ACHP). As shown in SI Appendix, Fig. S7B, ACHP reduced LPS/nigericin induction of IL-1β by 60%; however, in combination with OLT1177, the release of IL-1β was to the levels of unstimulated cells.

OLT1177 Prevents NLRP3 Inflammasome Formation. In J774A.1 cells, ASC immunoprecipitated with NLRP3 following LPS and nigericin, confirming the formation of the oligomer upon stimulation of the inflammasome (Fig. 2A). OLT1177 treatment resulted in a reduction in the NLRP3-mediated ASC recruitment (Fig. 2A, Left and Right). Using full-length recombinant human NLRP3 protein, we next measured the effect of OLT1177 on the nucleotide-binding domain of NLRP3. Recombinant NLRP3 exhibited ATPase activity (Fig. 2B), which was inhibited by OLT1177 at 1 and 10 μM (Fig. 2B). In the same assay, known inhibitors of the NLRP3 inflammasome, BAY and MNS, were used as positive controls (16, 17).

We next investigated the effect of OLT1177 on NLRP3 inflammasome formation using immunofluorescence and fluorescent resonance energy transfer (FRET) analysis. In unstimulated J774A.1 cells, NLRP3, ASC, and caspase-1 were diffuse in the cell (Fig. 2C and SI Appendix, Fig. S9A). However, following LPS and nigericin, ASC oligomerization was observed in the characteristic speck-like structure in the cytosol of J774A.1 cells (Fig. 2D). Cells treated with OLT1177 showed a reduction in speck structures, suggesting reduced inflammasome formation (Fig. 2E). ASC-NLRP3 association was further confirmed using

---

**Fig. 3.** OLT1177 has no effect on ATP-induced ion currents and on NLRC4 and AIM2 inflammasomes. (A) Representative current change of whole-cell patch-clamp measurements performed on human U937 cells primed with LPS (1 μg/mL, 5 h) and treated with BzATP (100 μM) to induce P2X7R activation. (B) Treatment with 100 μM OLT1177 in parallel cultures following BzATP. (C) Analysis of multiple measurements of BzATP-induced current changes (ΔI_BzATP) in the absence and presence of OLT1177 (0.1 nM and 100 μM, Wilcoxon signed-rank test). ΔI_BzATP values are shown as individual data points, bars represent median, and whiskers percentiles 25 and 75. (D and E) Mean ± SEM of secreted mature IL-1β and TNFα from J774A.1 cells stimulated with LPS and flagellin (Flag) in the presence of OLT1177. (F and G) Mean ± SEM of secreted mature IL-1β and TNFα from J774A.1 cells stimulated with LPS and Poly (dA:dT) in the presence of OLT1177 as measured in the supernatants. Data are derived from three independent experiments.

Marchetti et al.  
PNAS  |  Published online January 29, 2018  |  E1533
FRET. FRET positivity requires the distance between two molecules, in this case NLRP3 and ASC, to be less than 30 nm. As shown in Fig. 2G, LPS and nigericin stimulation of J774A.1 cells showed higher FRET intensity for NLRP3 and ASC, indicating inflammasome oligomerization. Following treatment with OLT1177, the association between these two proteins was significant lower (Fig. 2H and I). FRET analysis was also conducted to measure the proximity of NLRP3 and caspase-1 (SI Appendix, Fig. S9A). OLT1177 reduced NLRP3 and caspase-1 association following LPS and nigericin (Fig. 2H and SI Appendix, Fig. S9). Taken together, these data demonstrate that OLT1177 reduces the release of mature IL-1β by preventing NLRP3 inflammasome oligomerization.

OLT1177 Has No Effect on ATP-Induced Ion Current and Has No Effect on AIM2 and NLRC4 Inflammasomes. We next investigated the effect of OLT1177 on K⁺ efflux, a common activator of inflammasome function via activation of the P2X7 receptor (P2X7R) by extracellular ATP (18, 19). Ion current was measured in human LPS-primed monocytic U937 cells by whole-cell patch-clamp measurements. Two successive applications of 100 μM 2′(3′)-O-(4-benzoylbenzoyl)adenosine-5′-triphosphate tri(triethylammonium) salt (BzATP) resulted in the expected current change due to P2X7R activation (Fig. 3A); however, this was not affected by OLT1177 (Fig. 3B and C). The lack of effect of OLT1177 on ion flux was confirmed using Xenopus laevis oocytes, which heterologously express human P2X7R. OLT1177 had no effect on ion flux in oocytes when treated with BzATP (SI Appendix, Fig. S10). We conclude that OLT1177 inhibits NLRP3 inflammasome activation by a mechanism downstream of P2X7R.

To investigate the potential effect of OLT1177 on other inflammasomes, murine macrophages were primed with LPS and stimulated with either flagellin to activate the NLRC4 inflammasome or the dsDNA analog Poly(dA:dT) to activate the AIM2 inflammasome. The release of IL-1β and TNFα was determined. Compared with the levels induced by the agonists, OLT1177 showed no effect on the release of these cytokines following NLRC4 (Fig. 3D and E) or AIM2 (Fig. 3F and G) inflammasome activation. These data indicate that OLT1177 is specific for the NLRP3 inflammasome.

OLT1177 Reduces IL-1β Release in Freshly Obtained Human Blood Neutrophils. Neutrophil recruitment and tissue infiltration are hallmarks of the inflammatory response to injury and infection. Therefore, we investigated the effect of OLT1177 on freshly obtained human blood neutrophils following LPS and ATP stimulation. Processing and release of IL-1β precursor in primary human neutrophils was observed in cells stimulated with LPS and ATP (Fig. 4A). OLT1177 prevented the release of IL-1β (Fig. 4A) without affecting the total intracellular pool of the IL-1β precursor (Fig. 4B). Treatment of neutrophils with OLT1177 also reduced caspase-1 activity at 50 and 10 μM (Fig. 4C) without affecting il1b, caspase1, and nlrp3 mRNA levels (Fig. 4D–F).

OLT1177 Reduces the Severity of LPS-Induced Systemic Inflammation in Vivo. We next examined the efficacy of OLT1177 treatment in mice challenged with LPS-induced systemic inflammation.
As shown in Fig. 5 A–C, OLT1177 significantly reduced peritoneal fluid myeloperoxidase (MPO) by 80%, the neutrophil chemokine (C-X-C motif) ligand 1 (CXCL1) by 30%, and IL-6 by 44%. The total IL-1β content in lung, liver, spleen, and skeletal muscle was also significantly decreased (Fig. 5D); no significant changes were detected for TNFα content in these tissues (Fig. 5E).

**OLT1177 Increases Oxidative Metabolism in Vivo.** Marked alterations in muscle metabolism are observed during acute and chronic inflammation (20, 21). We investigated the effect of OLT1177 on metabolic changes in muscle following LPS-induced systemic inflammation. Muscle tissue was excised 2 h after LPS administration and examined for metabolic changes (Fig. 6). Treatment of mice with OLT1177 decreased metabolites of oxidative stress with increased reduced glutathione (GSH) and decreased oxidized glutathione (GSSG) levels, leading to an increased GSH/GSSG ratio (Fig. 6A–C). Improved glutathione homeostasis in OLT1177-treated mice could be explained, in part, by an increase in the NADPH-generating pentose phosphate pathway, for antioxidant effects or to sustain nucleoside anabolism, which is reflected by increased ribose phosphate levels (Fig. 6D). Since pentose phosphate moieties can also fuel the nucleoside biosynthetic pathways, we determined the relative levels of high energy purine nucleosides (ATP) and the total levels of adenylate metabolites (ATP, ADP, and AMP). As shown in Fig. 6E and F, higher levels of ATP were measured in muscle tissue from mice treated with OLT1177. These higher levels of adenylate metabolites can be due to increased adenylate synthesis or decreased consumption of high energy phosphate compounds, both hallmarks of cell activation following LPS stimulation (22). Consistent with a reduction in oxidative stress, steady-state levels of TCA cycle intermediate α-ketoglutarate were increased in OLT1177-treated animals (Fig. 6G). Treatment with OLT1177 also showed accumulation of citrate and decreased levels of oxaloacetate (Fig. 6H and I). These data are indicative of activation of early oxidative reactions of mitochondrial metabolism. Consistent with increased oxidative metabolism, tissue levels of the proinflammatory metabolic marker succinate were decreased in response to OLT1177 administration (Fig. 6J).

**Effects of Treatment with OLT1177 on Constitutive Kinase Phosphorylation in Vivo.** Mice were treated with OLT1177, and spleen cells were isolated and studied ex vivo for changes in phosphorylation of NF-κB, IκB, IKK, and interleukin-1 receptor-associated kinase 4 (IRAK4). As shown in Fig. 7A, compared with vehicle-treated mice, steady-state constitutive phosphorylated NFKB was significantly reduced in mice treated with OLT1177 at the time of spleen cell isolation. There were no statistically significant changes in the other kinases (Fig. 7B–D). However, when spleen cells from OLT1177-treated mice were activated in vitro with LPS, there was a significant reduction in phosphorylated NF-κB, IκB, and IKK after 30 min, with no change in IRAK4 (Fig. 7E–H). Thus, OLT1177 primes these kinases in vivo to be less responsive to an inflammatory stimulus.

**OLT1177 Reduces IL-1β Release in Cells with NLRP3 Mutations.** OLT1177 was tested in adherent monocytes from patients affected by cryopyrin-associated periodic syndrome (CAPS), a rare autoinflammatory disease characterized by gain-of-function mutations in NLRP3 (23). Patients with CAPS suffer from recurrent episodes of systemic inflammation, fever, and debilitation (24, 25). Blood monocytes isolated from two CAPS patients were stimulated with LPS in the presence and absence of OLT1177, which was added 30 min following LPS. As shown in Fig. 8, OLT1177 reduced IL-1β levels in the supernatants by 84% and 36%, respectively.
Seven of 35 subjects reported a total of

event (AE) during the course of the study. Five of the seven

events occurred after a single dose of OLT1177, and two oc-
curred during the multidose regimen (both in the 100-mg
dose group). The reported AEs were considered to be unrelated
to OLT1177 by the investigator, and each resolved spontaneously.
Physical examination in the subjects exposed to OLT1177
revealed no change from the predrug examination. Systolic and
diastolic blood pressure, heart rate, and body temperature
showed minor fluctuations from baseline to the end of
the study. Overall, there was no correlation between changes
in vital signs and OLT1177 dose or timing of treatment. No sig-
nificant changes were observed in hematologic or coagulation
values at any time during the study, compared with baseline
values. In addition, there were no significant changes from
baseline in serum lipids, urinalysis, liver function enzymes, or
acute phase proteins in any cohort after eight consecutive days
of up to 1,000-mg dosing.

**Discussion**

Although inhibition of the NLRP3 inflammasome reduces infl-

human Pharmacokinetic Profile. Following a single oral
dose, the group mean plasma maximum concentrations (Cmax)
were 2,700 ng/mL for the 100-mg dose, 9,800 ng/mL for the 300-mg
dose, and 32,000 ng/mL for the 1,000-mg dose (Fig. 9). The mean plasma
elimination half-life for each group was 23.0, 22.8, and 24.2 h for the
100-mg, 300-mg, and 1,000-mg dose groups, respectively. Mean
pharmacokinetic parameters for OLT1177 after a single dose in
fasted subjects are summarized in SI Appendix, Table S1. Plasma
OLT1177 exposure was also measured after repeated daily oral
dosing. Mean plasma concentrations of OLT1177 (±SD) on the
first (day 1) and last (day 8) of 8 d of oral dosing are presented in SI
Appendix, Fig. S11. The group mean maximum concentrations
on day 8 were 4,800 ng/mL for the 100-mg dose, 15,800 ng/mL for the
300-mg dose, and 41,400 ng/mL for the 1,000-mg dose. The plasma
elimination half-life for each multidose group on day 8 and other
pharmacokinetic parameters for OLT1177 after multiple doses
in fasted subjects are summarized in SI Appendix, Table S2.

OLT1177 Safety Profile. Seven of 35 subjects reported a total of
seven treatment-emergent adverse events (SI Appendix, Table S3),
and one subject reported a non–treatment-emergent adverse

Fig. 6. OLT1177 reduces muscle oxidative stress and increases oxidative metabolism in vivo. Metabolomic analyses were performed on muscle 2 h following LPS challenge from mice treated with OLT1177 or vehicle. Mean ± SEM in arbitrary units (AU) for reduced glutathione (GSH) (A); oxidized glutathione (GSSG) (B); GSH/GSSG ratios (C); ribose phosphate (D); ATP (E); and total adenylate pool (F); α-ketoglutarate (G); citrate (H); oxaloacetate (I); and succinate (J). n = 3 mice per group. **P < 0.01, *P < 0.05.

**Human Pharmacokinetic Profile.** Following a single oral
dose, the group mean plasma maximum concentrations (Cmax)
were 2,700 ng/mL for the 100-mg dose, 9,800 ng/mL for the 300-mg
dose, and 32,000 ng/mL for the 1,000-mg dose (Fig. 9). The mean plasma
elimination half-life for each group was 23.0, 22.8, and 24.2 h for the
100-mg, 300-mg, and 1,000-mg dose groups, respectively. Mean
pharmacokinetic parameters for OLT1177 after a single dose in
fasted subjects are summarized in SI Appendix, Table S1. Plasma
OLT1177 exposure was also measured after repeated daily oral
dosing. Mean plasma concentrations of OLT1177 (±SD) on the
first (day 1) and last (day 8) of 8 d of oral dosing are presented in SI
Appendix, Fig. S11. The group mean maximum concentrations
on day 8 were 4,800 ng/mL for the 100-mg dose, 15,800 ng/mL for the
300-mg dose, and 41,400 ng/mL for the 1,000-mg dose. The plasma
elimination half-life for each multidose group on day 8 and other
pharmacokinetic parameters for OLT1177 after multiple doses
in fasted subjects are summarized in SI Appendix, Table S2.

**OLT1177 Safety Profile.** Seven of 35 subjects reported a total of
seven treatment-emergent adverse events (SI Appendix, Table S3),
and one subject reported a non–treatment-emergent adverse

**Discussion**

Although inhibition of the NLRP3 inflammasome reduces infl-

Human Pharmacokinetic Profile. Following a single oral dose,
the group mean plasma maximum concentrations (Cmax) were
2,700 ng/mL for the 100-mg dose, 9,800 ng/mL for the 300-mg dose,
and 32,000 ng/mL for the 1,000-mg dose (Fig. 9). The mean plasma
elimination half-life for each group was 23.0, 22.8, and 24.2 h for the
100-mg, 300-mg, and 1,000-mg dose groups, respectively. Mean
pharmacokinetic parameters for OLT1177 after a single dose in
fasted subjects are summarized in SI Appendix, Table S1. Plasma
OLT1177 exposure was also measured after repeated daily oral
dosing. Mean plasma concentrations of OLT1177 (±SD) on the
first (day 1) and last (day 8) of 8 d of oral dosing are presented in SI
Appendix, Fig. S11. The group mean maximum concentrations
on day 8 were 4,800 ng/mL for the 100-mg dose, 15,800 ng/mL for the
300-mg dose, and 41,400 ng/mL for the 1,000-mg dose. The plasma
elimination half-life for each multidose group on day 8 and other
pharmacokinetic parameters for OLT1177 after multiple doses
in fasted subjects are summarized in SI Appendix, Table S2.

**OLT1177 Safety Profile.** Seven of 35 subjects reported a total of
seven treatment-emergent adverse events (SI Appendix, Table S3),
and one subject reported a non–treatment-emergent adverse

**Discussion**

Although inhibition of the NLRP3 inflammasome reduces infl-

diseases (6, 17, 26), there is currently no approved inflamma-
some inhibitor for human use. Here, we characterize the sulfonyl
triazole compound OLT1177 as a specific inhibitor of the
NLRP3 inflammasome, with no effect on the NLRC4 and
AIM2 inflammasomes. Unlike other NLRP3 inhibitors (27), we
report here the findings of OLT1177 administered orally to
healthy subjects in a phase 1 study. As presented, OLT1177 was
safe and well-tolerated and achieved meaningful exposure and a
long half-life without any clinical, hematological, or organ tox-
icities observed at any dose tested.

In addition, adherent monocytes from two patients with CAPS
stimulated with LPS and released less IL-1β in vitro in the
presence of 1 μM OLT1177.

We investigated the properties OLT1177 in human blood
monocyte-derived macrophages, human and murine cell lines,
and primary human blood neutrophils. Neutrophils play a
pathological role in many acute diseases, and elevated blood
neutrophil counts are characteristic of autoinflammatory dis-

cases mediated by IL-1β: for example, acute gout flares (28–30)
and familial Mediterranean fever (31–33). We observed that
OLT1177 reduces the processing of the IL-1β precursor in freshly
obtained human neutrophils, with no change in caspase1, nlrp3, and
illb mRNA.

OLT1177 treatment consistently reduced IL-1β release from
human blood macrophages, differentiated THP-1 cells, and
the murine macrophage cell line J774A.1. We observed that the in vitro
centration of OLT1177 necessary to reduce IL-1β differed among
types and experimental conditions. We also compared
OLT1177 with MCC950, a reported NLRP3 inflammasome
inhibitor (6) in J774A.1 cells. OLT1177 reduced IL-1β secretion in a comparable manner compared with MCC950 following
activation of the NLRP3 inflammasome with LPS and ATP (SI
Appendix, Fig. S8). Nevertheless, OLT1177 significantly reduced IL-
1β release at 1 μM or lower concentrations in vitro. By comparison,
mean peak plasma levels after a single oral dose in humans reached
concentrations of 20.3, 73.6, and 240.3 μM, respectively, for doses of
100, 300, and 1,000 mg per subject. Subjects also received 100, 300,
and 1,000 mg/d for eight consecutive days, which resulted in mean
maximum plasma concentrations at steady state of 36.0, 118.6, and
310.9 μM, respectively. Thus, based on the observed in vitro potency
levels, OLT1177 reaches effective plasma levels in vivo at molar
concentrations greater than 100-fold those needed to inhibit
activation of the NLRP3 inflammasome in vitro.

NLRP3 inflammasome formation also induces maturation and
release of IL-18. Consistent with inhibition of the NLRP3
inflammasome activation, OLT1177 significantly reduced IL-
18 release in human monocyte-derived macrophages (70% inhibition at 1 μM). Preclinical studies reveal that IL-18 is a target in several models of inflammation (34), including heart failure
(35) and macrophage activation syndrome (MAS) (36), each
treated with IL-1β blockade by the IL-1β antagonist anakinra.
These and other data (35) support the concept that IL-1 drives
the activation of caspase-1, resulting in increased IL-18 process-
ing and release. In patients with CAPS, a classic NLRP3 gain-of-
function disease, blocking IL-1 with anakinra reduced caspase-1
blood monocyte caspase-1 mRNA levels (37).

FRET analysis confirmed that LPS/nigericin treatment results in
the formation of NLRP3-ASC and NLRP3-(pro)caspase-1 complexes
at a distance of less than 30 nm, which was significantly re-
duced in the presence of OLT1177. Inhibition of the NLRP3-ASC
degomerization by OLT1177 was confirmed by immunoprecipita-
tion. The central domain of NLRP3 exhibits nucleotide-binding
interaction with the NLRP3 protein. OLT1177 inhibits IL-1β...

Fig. 7. OLT1177 reduces phosphorylation of NF-κB. (A–D) Mean ± SEM of NF-κB, IkB, IKK, and IRAK4 phosphorylation measured in fresh CD11b⁺CD3⁻ spleen-derived cells from mice treated with saline (vehicle) or OLT1177 under steady-state conditions. (E–H) Mean ± SEM of NF-κB, IkB, IKK, and IRAK4 phosphorylation measured in CD11b⁺CD3⁻ spleen-derived cells from mice treated with saline (vehicle) or OLT1177 stimulated for 30 min with LPS. n = 3 mice per group. **P < 0.01, *P < 0.05.

Marchetti et al.

PNAS | Published online January 29, 2018 | E1537
and the induction of proinflammatory succinate levels. OLT1177 also reduced muscle succinate accumulation, with LPS (100 ng/mL) for 18 h in the presence of vehicle (PBS) or OLT1177 (1 μM) (OLT). Vehicle and OLT1177 were added 30 min after LPS.

Immunofluorescent Microscopy and Fluorescent Resonance Energy Transfer (FRET) Measurements. Details on flow cytometry to assess levels of phosphokinases can be found in SI Appendix.

Whole-Cell Patch-Clamp Recordings. For electrophysiological recordings, U937 cells were placed in poly-L-lysine-coated cell culture dishes (Nunc) as previously described (47). Briefly, after incubation with 1 μg/mL LPS from Escherichia coli (L2654; Sigma-Aldrich) for 5 h, whole-cell patch-clamp recordings were performed at room temperature. Cells were clamped to −60 mV, OLT1177 Synthesis. The drug substance was manufactured by alkylation of sodium methanesulfonate with 3-bromopropionitrile to yield methylsulfonylpropionitrile (crude drug substance). The crude drug substance was then purified by dissolution into acetone, filtration of the sodium bromide byproduct, solvent exchange via distillation, and recrystallization from ethanol.

Inflammation and Inflammation. For electrophysiological recordings, J774A.1 cells were stimulated as described above. After washing with PBS, the cells were fixed and permeated with 70–30 acetone–methanol as previously described (45). Briefly, cells were placed in a humidified slide chamber blocked for 1 h in 10% normal donkey serum (Jackson Immunologicals). After removal of the donkey serum, the primary antibodies to NLRP3 (Cryo-2; AdipoGen), caspase-1 (sc-514; Santa Cruz Biotechnology), and ASC (D2WB8U; Cell Signaling) or isomolar, species-specific anti-igg (R&D Systems, Inc.) were added and incubated overnight at 4 °C. The slides were then washed three times with PBS, and cells were incubated for 1 h at room temperature with donkey anti-mouse-Alexa555 (Life Technologies) or donkey anti-rabbit-Alexa488 (Life Technologies) conjugated secondary antibodies. Nuclei were stained with DAPI (Life Technologies). FRET images were acquired using a Marianas Imaging Station (Intelligent Imaging Innovations) using a Zeiss 63 Plan-Apochromat objective (1.4 N.A.), a Sutter Xenon light source, and a Cooke SensiCam (The Cooke Corporation) as previously described (45). The FRET was calculated as FRET = Transfer − (FD/D) − (Fa/Aa) as reported (46).

Flow Cytometry. Details on flow cytometry to assess levels of phosphokinases can be found in SI Appendix.

Inflammasome Stimulation. Details for NLRP3 inflammasome formation in HMDM, human neutrophils, and J774A.1 murine macrophages are presented in SI Appendix.

Immunoprecipitation. Details for the immunoprecipitation can be found in SI Appendix.

OLT1177 Synthesis. The drug substance was manufactured by alkylation of sodium methanesulfonate with 3-bromopropionitrile to yield methylsulfonylpropionitrile (crude drug substance). The crude drug substance was then purified by dissolution into acetone, filtration of the sodium bromide byproduct, solvent exchange via distillation, and recrystallization from ethanol.

Methods

OLT1177 Synthesis. The drug substance was manufactured by alkylation of sodium methanesulfonate with 3-bromopropionitrile to yield methylsulfonylpropionitrile (crude drug substance). The crude drug substance was then purified by dissolution into acetone, filtration of the sodium bromide byproduct, solvent exchange via distillation, and recrystallization from ethanol.

Inflammasome Stimulation. Details for NLRP3 inflammasome formation in HMDM, human neutrophils, and J774A.1 murine macrophages are presented in SI Appendix.

Immunoprecipitation. Details for the immunoprecipitation can be found in SI Appendix.

Immunofluorescent Microscopy and Fluorescent Resonance Energy Transfer Analysis. J774A.1 cells were stimulated as described above. After washing with PBS, the cells were fixed and permeated with 70–30 acetone–methanol as previously described (45). Briefly, cells were placed in a humidified slide chamber blocked for 1 h in 10% normal donkey serum (Jackson Immunologicals). After removal of the donkey serum, the primary antibodies to NLRP3 (Cryo-2; AdipoGen), caspase-1 (sc-514; Santa Cruz Biotechnology), and ASC (D2WB8U; Cell Signaling) or isomolar, species-specific anti-igg (R&D Systems, Inc.) were added and incubated overnight at 4 °C. The slides were then washed three times with PBS, and cells were incubated for 1 h at room temperature with donkey anti-mouse-Alexa555 (Life Technologies) or donkey anti-rabbit-Alexa488 (Life Technologies) conjugated secondary antibodies. Nuclei were stained with DAPI (Life Technologies). FRET images were acquired using a Marianas Imaging Station (Intelligent Imaging Innovations) using a Zeiss 63 Plan-Apochromat objective (1.4 N.A.), a Sutter Xenon light source, and a Cooke SensiCam (The Cooke Corporation) as previously described (45). The FRET was calculated as FRET = Transfer − (FD/D) − (Fa/Aa) as reported (46).

Flow Cytometry. Details on flow cytometry to assess levels of phosphokinases can be found in SI Appendix.
and transmembrane currents were recorded using an EPC-9 amplifier (HEKA) and acquired via an IPC-16 interface with Pulse software (HEKA). A 100-nM stock solution of (2′3′-O-(β-D-ribofuranosyl)adenosine-5′-triphosphate (trithylammonium) salt (BzATP) (Jena Bioscience) was prepared and dissolved in the bath solution to a 100-nM working solution and applied via a pressure-driven micropipet system.

In Vivo LPS Challenge. Animal protocols were approved by the University of Colorado Health Sciences Center Animal Care and Use Committee. C57BL/6j male mice, 22 to 26 g (The Jackson Laboratory), were treated with 200 μg LPS (Olt1177 in 200 μL of saline or the matching volume of saline (saline) intraperitoneally (i.p.) every 12 h for five doses. One hour after the last dose of OLT1177 or saline, the animals were injected i.p. with 200 μL of LPS (E. coli, 055:B5; Sigma-Aldrich) at 5 mg/kg and killed after 2 h. Cytokines were measured in the peritoneal fluid and in homogenates of spleen, lung, liver, and skeletal muscle (quadriceps). Tissue homogenates were centrifuged at 13,000× g for 20 min at 4 °C, and the supernatants were assayed for cytokine levels. The cytokine concentrations were corrected for total protein content. For experiments with peritoneal lavage, 10 ml of cold PBS were injected in the peritoneal cavity before organ collection. The peritoneal lavage fluids were then centrifuged at 1,000 × g for 5 min, and the supernatants were used for cytokine measurement.

Metabolomics Analysis. Metabolomics analysis was performed, and details can be found in SI Appendix.

CAPS Patients. Blood samples from two CAPS patients positive for the mutation of the nrfrp3 gene were taken after informed consent by patients or their legal guardian and as approved by the “G. Gaslini” Ethical Board.

Human Safety and Pharmacokinetic Study. Details of the human study can be found in SI Appendix.

ACKNOWLEDGMENTS. We thank Ralph J. A. Mass and Niklas Lonnemann for assistance in cytokine measurements; and Julie R. Haines for assistance in the metabolomics analysis. We also thank G. Schmalzing and R. Hausmann (Rheinisch-Westfälische Technische Hochschule Aachen University) for providing us the human PZXR1 data and for their assistance and support. These studies are supported by NIH Grant AI-15614, the Interleukin Foundation, Olatec Therapeutics LLC, and German Research Foundation Grant GR 1094/7-1.